What is Karius?
Founded in 2014, Karius specializes in the development of genomic insights for infectious diseases. The company's core technology platform enables the identification of pathogens directly from blood samples, bypassing the limitations of traditional culture-based diagnostic methods. By providing a comprehensive view of the microbial landscape, Karius empowers healthcare providers to make life-saving treatment decisions with unprecedented speed and accuracy. The company operates at the intersection of biotechnology and data science, effectively bridging the gap between complex genomic data and clinical utility. Its market position is defined by its commitment to improving patient outcomes in hospital settings, particularly for immunocompromised patients and those with undiagnosed, severe infections.
How much funding has Karius raised?
Karius has raised a total of $320M across 4 funding rounds:
Other Financing Round
$5M
Series A
$50M
Unspecified
$165M
Series C
$100M
Other Financing Round (2014): $5M with participation from Data Collective, Innovation Endeavors, and Lightspeed Venture Partners
Series A (2017): $50M led by Innovation Endeavors, Pacific 8 Ventures, Tencent, Data Collective, and Lightspeed Venture Partners
Unspecified (2020): $165M supported by Khosla Ventures, General Catalyst, SoftBank Vision Fund 21, HBM Healthcare Investments, and LightSpeed Venture Partners
Series C (2024): $100M featuring General Catalyst, HBM Healthcare Investments, Gilde Healthcare, 5AM Ventures, Seventure Partners, and Khosla Ventures
Key Investors in Karius
General Catalyst
A venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors, including healthcare and enterprise software.
HBM Healthcare Investments
A publicly traded investment company dedicated to the global healthcare sector, targeting growth opportunities driven by medical advancements and innovative therapies.
Lightspeed Venture Partners
A global multistage venture capital firm that partners with founders from seed through IPO, with a strong focus on technology and infrastructure.
What's next for Karius?
With the successful closure of its latest funding round, Karius is well-positioned to accelerate its commercial expansion and further refine its diagnostic pipeline. The strategic capital will likely be deployed to enhance the company's laboratory infrastructure, broaden its clinical research initiatives, and scale its sales and marketing operations to reach a wider network of healthcare institutions. As the company moves deeper into its growth phase, the focus will remain on integrating its genomic insights into standard clinical workflows, thereby solidifying its status as an essential partner for hospitals and health systems globally. The continued support from its diverse investor base provides the necessary runway to navigate the complexities of the healthcare market while maintaining a rigorous focus on scientific innovation and operational excellence.
See full Karius company page
